You searched for Martina Garau

We found for

Insight
January 2023

Combination Therapies: A Step Forward to the Value Attribution Problem

Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

The Lower Drug Costs Now Act and Pharmaceutical Innovation

How is Quality of Life Measured for Health Technology Assessments?

Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?

International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making

Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?

Unrelieved Pain in Palliative Care in England

How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Market Access

Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

Policy Options for Formulary Development in Middle-income Countries

Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study

Latest Research & Publications

All Publications

We found for

Filter results by

Combination Therapies: A Step Forward to the Value Attribution Problem

Navigating the Landscape of Digital Health – United Kingdom

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

The Lower Drug Costs Now Act and Pharmaceutical Innovation

How is Quality of Life Measured for Health Technology Assessments?

Resource Allocation in Public Sector Programmes: Does the Value of a Life Differ Between Governmental Departments?

International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making

Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making?

Unrelieved Pain in Palliative Care in England

How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy

Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward

R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C

Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence

Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries

Policy Options for Formulary Development in Middle-income Countries

Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study